EUVIMEDEUVIMED entdecken
Crossref

Beyond efficacy: Insights from the norursodeoxycholic acid phase III trial in metabolic dysfunction-associated steatotic liver disease

Ling-Ying Yu, Xian-Feng Zhang

World Journal of Hepatology · 27.08.2026 · 18 (8)

DOI: 10.4254/wjh.117543 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Hepatology, online erschienen am 27.08.2026. Verfasst von Ling-Ying Yu und 1 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The therapeutic landscape for metabolic dysfunction-associated steatotic liver disease (MASLD) is undergoing rapid transformation with recent drug approvals. This editorial contextualizes a recent phase III trial of norursodeoxycholic acid within this dynamic progress. Panuganti et al recently published a study in World Journal of Hepatology , while demonstrating significant alanine aminotransferase normalization and FibroScan-based liver stiffness improvement, the trial’s short duration (24 weeks), reliance on non-invasive endpoints, and absence of histological confirmation underscore persistent challenges in MASLD drug development.

Zitieren

APA

Yu, L., & Zhang, X. (2026). Beyond efficacy: Insights from the norursodeoxycholic acid phase III trial in metabolic dysfunction-associated steatotic liver disease. World Journal of Hepatology, 18(8). https://doi.org/10.4254/wjh.117543

Vancouver

Yu L, Zhang X. Beyond efficacy: Insights from the norursodeoxycholic acid phase III trial in metabolic dysfunction-associated steatotic liver disease. World Journal of Hepatology. 2026;18(8). doi:10.4254/wjh.117543

BibTeX
@article{Yu2026,
  author = {Yu, Ling-Ying and Zhang, Xian-Feng},
  title = {Beyond efficacy: Insights from the norursodeoxycholic acid phase III trial in metabolic dysfunction-associated steatotic liver disease},
  journal = {World Journal of Hepatology},
  year = {2026},
  volume = {18},
  number = {8},
  doi = {10.4254/wjh.117543}
}
Kostenlos starten →